Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
, 113 (5), 805-816

Diminishing Benefit of Smoking Cessation Medications During the First Year: A Meta-Analysis of Randomized Controlled Trials

Affiliations
Meta-Analysis

Diminishing Benefit of Smoking Cessation Medications During the First Year: A Meta-Analysis of Randomized Controlled Trials

Laura J Rosen et al. Addiction.

Abstract

Background and aims: Although smoking cessation medications have shown effectiveness in increasing abstinence in randomized controlled trials (RCTs), it is unclear to what extent benefits persist over time. This paper assesses whether the benefits of smoking cessation medications decline over the first year.

Methods: We selected studies from three systematic reviews published by the Cochrane Collaboration. RCTs of first-line smoking cessation medications, with 6- and 12-month follow-up, were eligible for inclusion. Meta-analysis was used to synthesize information on sustained abstinence (SA) at 6 versus 12 months and 3 versus 6 months, using the risk difference (RD) ('net benefit') between intervention and control group quit rates, the relative risk (RR) and the odds ratio (OR).

Results: Sixty-one studies (27 647 participants) were included. Fewer than 40% of intervention group participants were sustained abstinent at 3 months (bupropion: 37.1%; nicotine replacement therapy (NRT): 34.8%; varenicline: 39.3%); approximately a quarter were sustained abstinent at 6 months (bupropion: 25.9%; NRT: 26.6%; varenicline: 25.4%), and approximately a fifth were sustained abstinent at 12 months (bupropion: 19.9%; NRT: 19.8%%; varenicline: 18.7%). There was only a small decline in RR (3 months: 1.95 [95% confidence interval (CI) = 1.74-2.18, P < 0.0001]; 6 months: 1.87 (95% CI = 1.67-2.08 P < 0.0001); 12 months: 1.75 (95% CI = 1.56-1.95, P < 0.0001) between intervention and control groups over time, but a substantial decline in net benefit [3 months: RD = 17.3% (14.5-20.1%); 6 months: RD = 11.8% (10.0-13.7%); 12 months: RD = 8.2% (6.8-9.6%)]. The decline in net benefit was statistically significant between 3 and 6 [RD = 4.95% (95% CI = 3.49-6.41%), P < 0.0001] and 6 and 12 months [RD = 3.00% (95% CI = 2.36%-3.64%), P < 0.0001)] for medications combined and individual medications.

Conclusions: The proportion of smokers who use smoking cessation medications who benefit from doing so decreases during the course of the first year, but a net benefit still remains at 12 months.

Keywords: Bupropion (Zyban); cessation medications; meta-analysis; nicotine replacement therapy (NRT); sustained abstinence; varenicline (Chantix, Champix).

Figures

Figure 1
Figure 1
Sustained abstinence quit rates (QRs), risk differences (RDs) and relative risks (RRs) over time and treatment arm, for individual medications. NRT = nicotine replacement therapy; ITT = intent‐to‐treat
Figure 2
Figure 2
Forest plots for meta‐analyses of interaction terms (time by intervention arm), overall and for individual medications, for sustained abstinence quit rates 6‐12 months
Figure 3
Figure 3
Illustrative example using hypothetical data: how net benefit of medications decreases over time with declining quit rates and stable relative risk

Similar articles

See all similar articles

Cited by 8 articles

See all "Cited by" articles

References

    1. The Tobacco Atlas: Tobacco Deaths 2016. Available at: http://www.tobaccoatlas.org/topic/smokings-death-toll (accessed 22 December 2016) (Achived at http://www.webcitation.org/6wOMY1YIb on 11 January 2018).
    1. World Health Organization (WHO) . WHO Report on the Global Tobacco Epidemic, 2011: Warning About the Dangers of Tobacco. Geneva, Switzerland: WHO; 2011. (Available at: http://www.who.int/tobacco/global_report/2011/en/ (accessed 11 January 2018) (Archived at http://www.webcitation.org/6wOMtmIsP on 11 January 2018)
    1. World Health Organization . Tobacco: Fact Sheet 2017. Available at: http://www.who.int/mediacentre/factsheets/fs339/en (accessed 20 September 2017) (Archived at http://www.webcitation.org/6wONFjN7v on 11 January 2018).
    1. Jha P., Chaloupka F. The economics of global tobacco control. BMJ 2000; 321: 358–361. - PMC - PubMed
    1. Fiore M., Jaen C. R., Baker T., Bailey W., Benowitz N., Curry S. J. et al Treating Tobacco Use and Dependence: 2008 Update. Rockville, MD: US Department of Health and Human Services; 2008.

Publication types

Feedback